Healthcare: Healthcare Provider EQUIPMEN AB: Saudi Arabia 26 March 2024



US\$0.49bn Market Cap.

61.66% Free Float

US\$8.65mn Avg. Daily Value traded

Research Department Madhu Appissa, CFA Tel +966 11 836 5464, appissam@alrajhi-capital.com

Underweight

Price Target (SAR): 46.0

Current: 57.5

Upside/Downside: 20.0% below current

Valuation Multiples	23	24E	25E
P/E (x)	42.9	35.9	29.2
P/B (x)	3.6	3.5	3.3
ROE (%)	8.0	9.7	11.5

Major Shareholders

% Ownership

Bandar Saud Mohammed Al-Arifi	7.46
Barakat Saud Mohammed Al-Arifi	6.47
Bashir Saud Mohammed Al-Arifi	6.11

Price Performance	1 M	3M	YTD
Absolute	10.6%	27.2%	20.4%
Relative to TASI	10.1%	21.2%	15.3%

(SARmn)	2023	2024E	2025E
Revenue	799	978	1,077
Revenue growth	12.0%	22.3%	10.2%
Gross Profit	133	170	190
Gross margin	16.7%	17.4%	17.7%
EBIT	69	76	85
EBIT margin	8.6%	7.8%	7.9%
Net Income	40	48	59
Net Income margin	5.0%	4.9%	5.5%
Net Income growth	128.8%	19.6%	23.0%
EPS	1.3	1.6	2.0

Source: Company data, Al Rajhi Capital

Equipment House

Margins remain a concern, remain Underweight

Equipment House has a strong order backlog (current SAR 2.0 bn, >2.0x of its current revenues) and is expected to see notable jump in revenues in 2024 (+22% yo-y). However, rising competition in the space and the company's move to grow its order backlog notably in the recent years has bought in some compromise on the margins front. Moreover, the bulk of the order inflow has come from the relatively weaker margins in the non-medical O&M business, that includes supplying staffing solutions for the maintenance of the building. At the same time, the rise in SAIBOR has weighed on its interest cost as the company borrows for working capital needs. Moreover, delay on the government receivables has also been a concern. We slightly raise our revenue estimates for 2024 but trim our gross margins forecasts (now 17.4% versus 21% before) as uninspiring margin performance in 2023, particularly Q4 2023, as well as rising labor inflation makes us cautious. On a y-o-y basis, some margin improvement in 2024 is possible as the mix of trading revenues (better margins) increases, subsidiaries (reported as other activities) to make normalized margins in 2024 and we expect meat and food segment, that has been making losses to breakeven in 2024. At the same time, the benefits of operating leverage (G&A costs to grow at a slower pace) should help the operating margin. However, we do not consider any ECL reversals or provisions in 2024/2025. Thus, operating margin estimates for 2024 are 7.8%, lower than 8.6% in 2023 (ECL reversals helped operating profits in 2023).

(SAR mn)	Q4 2023	Q4 2022	Y-o-Y	Q3 2023	Q-o-Q	ARC est	vs ARC
Revenue	232	189	23%	212	9%	215	8%
Gross profit	35	34	4%	37	-4%	40	-11%
Gross margin	15.3%	18.0%		17.5%		18.5%	
Operating profit	23	(23)	NM	25	-7%	22	
Operating margin	10.0%	-11.9%		11.8%		10.0%	
Adj.* Operating Profit	13	17	-26%	14	-9%	17	-24%

-24% Adj. Operating margin 5.4% 9.0% 6.5% 7.7% Net profit 13 NM 17 -25% (26)14 5.6% 6.6% Net margin -13.9% 8.1% Adj.* Net profit 2 15 -85% 6 -62% 9 -75% Adj. Net margin 1.0% 8.0% 2.8% 4.3%

Source: Company data, Al Rajhi Capital; Note:* Adjusted for one-off ECL provisions and reversals

Q4 2023 Results

Figure 1

Q4 2023 Results: SMEH's Q4 2023 revenues grew 23% y-o-y coming at SAR 232mn, this was 8% above our expectations of SAR 215mn. The increase can be attributable to receiving and commencing new projects that were announced during previous periods. However, gross profit of SAR 35mn (+4% y-o-y, -4% g-o-q), came in 11% lower than our expectations. Gross margins were weak at 15.3% versus our expectations of 18.5% and preceding quarter's (Q3 2023) 17.5%. Despite weak gross profits, the reported profitability numbers were broadly in line as we believe ECL reversals were more than our expectations (SAR 11mn reversals vs. ARC estimate: SAR 5mn reversals). However, both adjusted operating profit and net profit came below expectations.



Valuations: Given that bulk of the growth is expected to come from O&M business alone, we now value the company on P/E methodology from SOTP earlier. The company has a notable order backlog and the market is pricing in the benefits of sharp growth in the revenues in the near future. To capture the growth in the next 2-3 years, we use the average EPS of 2024-2026 and apply a sustainable multiple of 23x (average growth beyond 2025 expected to be mid to high single digit) to derive our fair value of SAR 46/share (from SAR 45.35/share before). We maintain our Underweight recommendation on the stock and believe any signs of margin improvement or growth in high margin businesses such as medical O&M, subsidiaries and order inflow in trading business provide upside risks to our target price.

Figure 2 Valuations

P/E	Multiples
EPS - 2024/2025E/2026E (SAR)	2.0
Target P/E multiple	23x
Target price per share (SAR)	46.0
CMP (SAR)	57.5
Upside/(Downside)	-20.0%

Source: Al Rajhi Capital estimates



Financials

Figure 3 Income Statement

SARmn	2024E	2025E	2026E
Revenue	978	1,077	1,153
y-o-y growth	22.3%	10.2%	7.0%
Cost of sales	(808)	(887)	(944)
Gross Profit	170	190	209
y-o-y growth	27.8%	11.8%	9.7%
margins	17.4%	17.7%	18.1%
Selling and marketing expenses	(12)	(14)	(15)
General and admin. Expenses	(82)	(92)	(98)
Operating profit	76	85	96
y-o-y growth	11.0%	11.0%	13.0%
margins	7.8%	7.9%	8.3%
Finance cost	(29)	(24)	(22)
Pre-Tax Income	55	68	82
Zakat	(8)	(10)	(12)
Net Income/Net Profit (Losses)	48	59	71
y-o-y growth	19.6%	23.0%	19.2%
margins	4.9%	5.5%	6.1%
EPS	1.6	2.0	2.4
DPS	1.0	1.0	1.1

Source: Al Rajhi Capital estimates

Figure 5 Cash Flow Statement

SARmn	2024E	2025E	2026E
Cash flow from Operations	(19)	38	50
Cash flow from Investing	(41)	(45)	(48)
Cash flow from Financing	24	27	27
Change in cash	(36)	20	29
Cash and Cash Equivalents at the end of the year	37	56	85

Source: Al Rajhi Capital estimates

Figure 6	Key Ratios			
SARmn		2024E	2025E	2026E
ROA		6.9%	6.9%	0.0%
ROE		9.7%	11.5%	12.9%
Current Ratio		1.9x	1.8x	1.8x
Asset turnover rati	o	0.9x	0.9x	0.9x
Inventory turnover	ratio	6.7x	6.5x	6.4x
Receivables turno	ver ratio	1.9x	1.8x	1.8x
Payable turnover i	atio	8.9x	8.5x	8.8x
Cash Conversion	Cycle (Days)	209	213	216
Debt-Equity Ratio		0.6x	0.7x	0.7x
BVPS		16.5x	17.4x	18.6x
P/E		35.9x	29.2x	24.4x
P/B		3.5x	3.3x	3.1x

Source: Al Rajhi Capital estimates

Figure 4 Balance sheet

SARmn	2024E	2025E	2026E
Property, plant and equipment	43	47	49
Right of use of assets	40	48	53
Investment properties	32	32	32
Intangible assets	4	4	4
Total Non-current assets	118	130	138
Cash and cash equivalents	37	56	85
Trade receivables	567	614	657
Contract assets	196	215	231
Inventories	129	142	151
Prepaid expenses and other debt balan	87	95	94
Deferred expenses	12	12	12
Dues from Related Parties	19	19	19
Total Current assets	1,046	1,154	1,249
Total Assets	1,165	1,284	1,387
Short-term loans	267	321	378
Trade creditors	99	109	107
Payable expenses and other creditor ba	156	171	173
Provision for Legal Zakat	12	12	12
Other Current Liabilities	22	22	23
Total Current liabilities	556	635	693
Long-term loan	10	10	10
Employee Defined Benefit Liabilities	87	96	103
Lease liabilities	18	20	22
Total Non-current liabilities	114	126	135
Total Liabilities	670	761	827
Share capital	200	200	200
Statutory reserve	37	37	37
Retained earnings	262	291	329
Total Shareholders' Equity	499	528	565
Non-controlling equity	(4)	(5)	(6)
Total liabilities and equity	1,165	1,284	1,387

Source: Al Rajhi Capital estimates

SMEH

Healthcare: Healthcare Provider EQUIPMEN AB: Saudi Arabia 26 March 2024



IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by Al Rajhi (Capital (Al Rajhi), a company authorized to engage in securities activities in Saudi Arabia. Al Rajhi is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through Al Rajhi.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report.

Neither Al Rajhi nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

Al Raihi may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of Al Raihi,

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by Al Rajhi with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of Al Rajhi and Al Rajhi accepts no liability whatsoever for the actions of third parties in this respect. This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Rajhi Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Healthcare: Healthcare Provider EQUIPMEN AB: Saudi Arabia 26 March 2024



Disclaimer and additional disclosures for Equity Research

Disclaimer

This research document has been prepared by Al Rajhi Capital Company ("Al Rajhi Capital") of Riyadh, Saudi Arabia. It has been prepared for the general use of Al Rajhi Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Al Raihi Capital, Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Al Rajhi Capital. The information contained was obtained from various public sources believed to be reliable but we do not guarantee its accuracy. Al Rajhi Capital makes no representations or warranties (express or implied) regarding the data and information provided and Al Rajhi Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Al Rajhi Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Al Rajhi Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Al Rajhi Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document.

This research document and any recommendations contained are subject to change without prior notice. Al Rajhi Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Al Rajhi Capital or any of its affiliates to any $registration\ or\ licensing\ requirement\ within\ such\ jurisdiction.$

Explanation of Al Rajhi Capital's rating system

Al Rajhi Capital uses a three-tier rating system based on absolute upside or downside potential for all stocks under its coverage except financial stocks and those few other companies not compliant with Islamic Shariah law:

"Overweight": Our target price is more than 10% above the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Neutral": We expect the share price to settle at a level between 10% below the current share price and 10% above the current share price on a 12 month time horizon.

"Underweight": Our target price is more than 10% below the current share price, and we expect the share price to reach the target on a 12 month time horizon.

"Target price": We estimate target value per share for every stock we cover. This is normally based on widely accepted methods appropriate to the stock or sector under consideration, e.g. DCF (discounted cash flow) or SOTP (sum of the parts) analysis.

Please note that the achievement of any price target may be impeded by general market and economic trends and other external factors, or if a company's profits or operating performance exceed or fall short of our expectations.

Contact us

Mazen AlSudairi, CFA Head of Research Tel: +966 11 836 5468

Email: alsudairim@alrajhi-capital.com

Al Rajhi Capital

Research Department Head Office, King Fahad Road P.O. Box 5561, Riyadh 11432 Kingdom of Saudi Arabia

Email: research@alrajhi-capital.com

Al Rajhi Capital is licensed by the Saudi Arabian Capital Market Authority, License No. 07068/37